PharmaBlock Sciences (Nanjing) Balance Sheet Health
Financial Health criteria checks 4/6
PharmaBlock Sciences (Nanjing) has a total shareholder equity of CN¥2.9B and total debt of CN¥1.4B, which brings its debt-to-equity ratio to 48.1%. Its total assets and total liabilities are CN¥4.7B and CN¥1.9B respectively. PharmaBlock Sciences (Nanjing)'s EBIT is CN¥217.5M making its interest coverage ratio 5.6. It has cash and short-term investments of CN¥1.2B.
Key information
48.1%
Debt to equity ratio
CN¥1.38b
Debt
| Interest coverage ratio | 5.6x |
| Cash | CN¥1.24b |
| Equity | CN¥2.87b |
| Total liabilities | CN¥1.86b |
| Total assets | CN¥4.73b |
Recent financial health updates
Recent updates
PharmaBlock Sciences (Nanjing), Inc.'s (SZSE:300725) P/E Is Still On The Mark Following 40% Share Price Bounce
Sep 30
PharmaBlock Sciences (Nanjing)'s (SZSE:300725) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Aug 23We Think PharmaBlock Sciences (Nanjing) (SZSE:300725) Is Taking Some Risk With Its Debt
Jul 31PharmaBlock Sciences (Nanjing) (SZSE:300725) Is Increasing Its Dividend To CN¥0.31
Jun 12PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely
Apr 21PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) Looks Just Right With A 25% Price Jump
Mar 07Financial Position Analysis
Short Term Liabilities: 300725's short term assets (CN¥2.5B) exceed its short term liabilities (CN¥609.7M).
Long Term Liabilities: 300725's short term assets (CN¥2.5B) exceed its long term liabilities (CN¥1.2B).
Debt to Equity History and Analysis
Debt Level: 300725's net debt to equity ratio (5%) is considered satisfactory.
Reducing Debt: 300725's debt to equity ratio has increased from 13.2% to 48.1% over the past 5 years.
Debt Coverage: 300725's debt is not well covered by operating cash flow (19.6%).
Interest Coverage: 300725's interest payments on its debt are well covered by EBIT (5.6x coverage).